XML 39 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Cash flows from operating activities:    
Net loss $ (25,732,707) $ (14,116,780)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 759,527 917,147
Stock-based compensation 2,227,145 2,636,445
Gain on sale of marketable securities   (83,750)
Loss on disposal of fixed assets   32,145
Change in fair value of warrant liability 9,974,685 (6,500,377)
Changes in operating assets and liabilities:    
Other receivables 19,432 252
Trade receivables (40,584) (281,709)
Prepaid and other current assets 170,667 465,514
Other assets, non-current 32,926 18,830
Accounts payable and accrued expenses (1,613,123) (142,120)
Accrued wind-down expenses (817,110) (820,708)
Deferred revenue (665) (4,541)
Deferred rent 69,997 1,034,088
Net cash used in operating activities (14,949,810) (16,845,564)
Cash flows from investing activities:    
Purchase of marketable securities (8,109,933) (10,223,957)
Proceeds from the sale and maturity of marketable securities 5,362,000 5,134,206
Purchases of property, plant and equipment (19,729) (330,740)
Proceeds from sale of property, plant and equipment   42,427
Net cash used in investing activities (2,767,662) (5,378,064)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 16,196,587 10,426,121
Proceeds from the exercise of stock options   2,386
Proceeds from the exercise of warrants, net of issuance costs 4,153,584  
Payments related to net share issuance of stock based awards (59,090) (396,201)
Repayment of capital lease obligations (18,521) (50,246)
Repayment of bonds payable (141,250) (130,000)
Net cash provided by financing activities 20,131,310 9,852,060
Increase (decrease) in cash and cash equivalents 2,413,838 (12,371,565)
Effects of foreign exchange rate changes on cash (12,411) (42,182)
Cash and cash equivalents, beginning of period 13,311,261 19,707,821
Cash and cash equivalents, end of period 15,712,688 7,294,074
Supplemental disclosure of cash flow information:    
Interest paid 40,114 56,585
Supplemental schedule of non-cash investing and financing activities:    
Stock issued for an option agreement 50,000 [1]  
Equipment acquired under a capital lease $ 21,721 [2]  
[1] In September 2012, we issued 24,753 shares of restricted common stock under the terms of an agreement with a developer of biological materials in return for certain product rights including an exclusive right of first offer to commercialize the developer’s products as may be developed on or before April 18, 2017.
[2] Represents the present value of future minimum capital lease payments for equipment leased in the third quarter of 2012.